Enhanced Detection of Mild Cognitive Impairment in Alzheimer's Disease: a Hybrid Model Integrating Dual Biomarkers and Advanced Machine Learning

Overview

Journal BMC Geriatr

Publisher Biomed Central

Date 2025 Jan 24

PMID 39849395

Authors

John Sahaya Rani Alex

R Roshini

G Maneesha

Jeetashree Aparajeeta

B Priyadarshini

Chih-Yang Lin

Chi-Wen Lung

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a complex, progressive, and irreversible neurodegenerative disorder marked by cognitive decline and memory loss. Early diagnosis is the most effective strategy to slow the disease's progression. Mild Cognitive Impairment (MCI) is frequently viewed as a crucial stage before the onset of AD, making it the ideal period for therapeutic intervention. AD is marked by the buildup of amyloid-beta (Aβ) plaques and tau neurofibrillary tangles (NFTs), which are believed to cause neuronal loss and cognitive decline. Both Aβ plaques and NFTs accumulate for many years before the clinical symptoms become apparent in AD. As a result, in this study, CerebroSpinal Fluid (CSF) biomarker information is combined with hippocampal volumes to differentiate between MCI and AD. For this, a novel two-stage hybrid learning model that leverages 3D CNN and the notion of a Fuzzy and Machine learning model is proposed. A 3D-CNN architecture is employed to segment the hippocampus from the structural brain 3D-MR images and quantify the hippocampus volume. In stage 1, the hippocampus volume is passed through thirteen machine learning models and fuzzy clustering for classifying symptomatic AD and healthy brain (Normal Control - NC). The CSF data is fuzzified to capture the inherent uncertainty and overlap in clinical data. The identified symptomatic AD data in the stage1 are further classified into MCI and AD with the aid of a fuzzified CSF biomarker in stage 2. The experimental work presented in this study utilized the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset. The proposed hybrid model achieved an average accuracy of 93.6% for distinguishing between NC and symptomatic AD and 93.7% for discriminating between MCI and AD. This approach enhances diagnostic accuracy and provides a more comprehensive assessment, allowing for earlier and more targeted therapeutic interventions.

References

Oh K, Chung Y, Kim K, Kim W, Oh I . Classification and Visualization of Alzheimer's Disease using Volumetric Convolutional Neural Network and Transfer Learning. Sci Rep. 2019; 9(1):18150. PMC: 6890708. DOI: 10.1038/s41598-019-54548-6. View

Bibi R, Yan Z, Ilyas M, Shaheen M, Singh S, Zeb A . Correction: Assessment of fall-associated risk factors in the Muslim community-dwelling older adults of Peshawar, Khyber Pakhtunkhwa, Pakistan. BMC Geriatr. 2024; 24(1):1. PMC: 10763672. DOI: 10.1186/s12877-023-04486-w. View

Tangaro S, Fanizzi A, Amoroso N, Bellotti R . A fuzzy-based system reveals Alzheimer's Disease onset in subjects with Mild Cognitive Impairment. Phys Med. 2017; 38:36-44. DOI: 10.1016/j.ejmp.2017.04.027. View

Lin W, Gao Q, Du M, Chen W, Tong T . Multiclass diagnosis of stages of Alzheimer's disease using linear discriminant analysis scoring for multimodal data. Comput Biol Med. 2021; 134:104478. DOI: 10.1016/j.compbiomed.2021.104478. View

Islam J, Zhang Y . Brain MRI analysis for Alzheimer's disease diagnosis using an ensemble system of deep convolutional neural networks. Brain Inform. 2018; 5(2):2. PMC: 6170939. DOI: 10.1186/s40708-018-0080-3. View

Thyreau B, Sato K, Fukuda H, Taki Y . Segmentation of the hippocampus by transferring algorithmic knowledge for large cohort processing. Med Image Anal. 2017; 43:214-228. DOI: 10.1016/j.media.2017.11.004. View

Lin W, Tong T, Gao Q, Guo D, Du X, Yang Y . Convolutional Neural Networks-Based MRI Image Analysis for the Alzheimer's Disease Prediction From Mild Cognitive Impairment. Front Neurosci. 2018; 12:777. PMC: 6231297. DOI: 10.3389/fnins.2018.00777. View

Rosen C, Hansson O, Blennow K, Zetterberg H . Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener. 2013; 8:20. PMC: 3691925. DOI: 10.1186/1750-1326-8-20. View

Dubois B, von Arnim C, Burnie N, Bozeat S, Cummings J . Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res Ther. 2023; 15(1):175. PMC: 10571241. DOI: 10.1186/s13195-023-01314-6. View

Uysal G, Ozturk M . Hippocampal atrophy based Alzheimer's disease diagnosis via machine learning methods. J Neurosci Methods. 2020; 337:108669. DOI: 10.1016/j.jneumeth.2020.108669. View

10.

Varghese T, Sheelakumari R, James J, Mathuranath P . A review of neuroimaging biomarkers of Alzheimer's disease. Neurol Asia. 2014; 18(3):239-248. PMC: 4243931. View

11.

Dubois B, Feldman H, Jacova C, Hampel H, Molinuevo J, Blennow K . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014; 13(6):614-29. DOI: 10.1016/S1474-4422(14)70090-0. View

12.

Xu B, Ling Y, Liu L, Liu Y, Lin Y, Lyu J . Potential prognostic value of CSF-targeted proteomics across the Alzheimer's disease continuum. BMC Geriatr. 2024; 24(1):501. PMC: 11157758. DOI: 10.1186/s12877-024-05104-z. View

13.

Schachter A, Davis K . Alzheimer's disease. Dialogues Clin Neurosci. 2011; 2(2):91-100. PMC: 3181599. View

14.

Ismail R, Parbo P, Madsen L, Hansen A, Hansen K, Schaldemose J . The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study. J Neuroinflammation. 2020; 17(1):151. PMC: 7203856. DOI: 10.1186/s12974-020-01820-6. View

15.

Rasmussen J, Langerman H . Alzheimer's Disease - Why We Need Early Diagnosis. Degener Neurol Neuromuscul Dis. 2020; 9:123-130. PMC: 6935598. DOI: 10.2147/DNND.S228939. View